Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb Company and AstraZeneca have reported the positive results from a Phase 3b clinical study of Onglyza (saxagliptin) 5mg drug.
Subscribe to our email newsletter
The 52-week analysis showed that saxagliptin tablet added to insulin (with or without metformin) reduced blood sugar levels (HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin).
University of Birmingham and Heart of England NHS Foundation, professor of Medicine, Anthony Barnett said that it is important to evaluate a compound’s ability to be used in combination with insulin to manage blood glucose control over the long term as many type 2 diabetes patients need insulin.
"This is the first longer- term study to report that Onglyza 5mg, used with insulin, maintains improvement in glucose control over 24 to 52 weeks in adult patients with type 2 diabetes," Barnett said.
In Europe, the once-daily 5mg Onglyza tablet is used to treat the adult patients suffering from type 2 diabetes mellitus.